Work

A phase 1/2 study of olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE): Results of the phase 1 study.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.e17020

Authors: Rana R. McKay, Wanling Xie, Archana Ajmera, Biren Saraiya, Mamta Parikh, Edmund Folefac, Adam C. Olson, Atish Dipankar Choudhury, David Johnson Einstein, Elisabeth I. Heath, Rahul Atul Parikh, Charles Kunos, S. Percy Ivy, Geoffrey Shapiro, Razelle Kurzrock

Institutions: Moores Cancer Center, Dana-Farber Cancer Institute, University of California San Diego, Rutgers Cancer Institute, UC Davis Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Duke Medical Center, Beth Israel Deaconess Medical Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, University of Kansas Medical Center, Summa Health System, National Cancer Institute

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3173040627

Cites:

Cited by: 7

Related to: 10